Doctor profile · Federal record
Dr. Mark Ash, M.D.
Dermatology Physician (CMS: Dermatology) · Clay, NY
- NPI 1710419379
- Accepts Medicare
- MIPS 82.5 / 100 · 2023
- 9 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
4106 Route 31 # 904
Clay, NY 130418789
(315) 500-3376
fax (315) 600-3376
Credentials & registration
- NPI registered
- March 2017 — 9 yrs on file
- Profile last updated
- January 23, 2026
- Year of graduation
- 2017 — 9 yrs since
- Specialty taxonomy
- 207N00000X — NUCC code
- State license (1)
- New York #309640
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1710419379. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
3,236
Distinct HCPCS
10
Medicare allowed
$186,647
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
17003 |
Destruction of precancer skin growth, 2-14 growths | 941 | 148 | $6 | |
J7345 |
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | 614 | 11 | $2 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 522 | 270 | $122 | |
17000 |
Destruction of precancer skin growth, 1 growth | 275 | 189 | $44 | |
17110 |
Destruction of skin growth, 1-14 growths | 243 | 173 | $101 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 118 | 95 | $87 | |
99204 |
New patient office or other outpatient visit, 45-59 minutes | 113 | 113 | $159 | |
11102 |
Biopsy of related skin growth, first growth | 111 | 94 | $72 | |
17004 |
Destruction of precancer skin growth, 15 or more growths | 40 | 25 | $162 | |
99215 |
Established patient office or other outpatient visit, 40-54 minutes | 38 | 20 | $172 |
In context: peer comparison
Among 1 peers in this city , average services per provider: 161. This provider delivers 20× the peer median.Open Payments
Industry payments received
All-time total
$3,301
Transactions
171
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| ABBVIE INC. | 28 | $521.68 | |
| Incyte Corporation | 13 | $346.32 | |
| Novartis Pharmaceuticals Corporation | 19 | $310.34 | |
| Regeneron Healthcare Solutions, Inc. | 11 | $286.30 | |
| Janssen Biotech, Inc. | 10 | $257.86 | |
| GENZYME CORPORATION | 8 | $241.90 | |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 10 | $235.21 | |
| Lilly USA, LLC | 10 | $178.70 | |
| Dermavant Sciences, Inc. | 20 | $160.61 | |
| PFIZER INC. | 17 | $151.32 | |
| UCB, Inc. | 6 | $144.85 | |
| E.R. Squibb & Sons, L.L.C. | 5 | $102.93 | |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $96.33 | |
| Arcutis Biotherapeutics, Inc. | 5 | $88.12 | |
| LEO Pharma Inc. | 5 | $87.67 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
1,195
Patients
744
Total drug cost
$143,028
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Ketoconazole | Generic | 211 | 126 | $4,031 |
| Clobetasol Propionate | Generic | 210 | 115 | $11,522 |
| Triamcinolone Acetonide | Generic | 142 | 96 | $1,370 |
| Fluorouracil | Generic | 140 | 106 | $13,268 |
| Mupirocin | Generic | 136 | 95 | $1,067 |
| Tacrolimus | Generic | 60 | 38 | $12,899 |
| Ciclopirox | Generic | 57 | 28 | $2,167 |
| Doxycycline Hyclate | Generic | 53 | 39 | $2,046 |
| Metronidazole | Generic | 50 | 32 | $2,979 |
| Valacyclovir (Valacyclovir Hcl) | Brand | 27 | 15 | $334 |
Hospital affiliations
Frequently asked questions
What is Dr. Mark Ash's medical specialty?
Dr. Mark Ash practices Dermatology Physician in Clay, NY.
Where does Dr. Mark Ash practice?
Dr. Mark Ash practices at 4106 Route 31 # 904, Clay, NY 130418789. Office phone: 3155003376.
What is Dr. Mark Ash's NPI?
Dr. Mark Ash's National Provider Identifier (NPI) is 1710419379, issued by NPPES.
Does Dr. Mark Ash accept Medicare assignment?
Yes. Dr. Mark Ash accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Mark Ash commonly perform?
Top Medicare-reported procedures in 2023: Destruction of precancer skin growth, 2-14 growths (HCPCS 17003); Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg (HCPCS J7345); Established patient office or other outpatient visit (HCPCS 99214). Source: CMS Medicare Physician & Other Practitioners file.